UPDATE : Monday, September 7, 2020
상단여백
Regulator to consider re-classifying choline alfoscerate as functional food by Kim Yun-mi 2019-11-06 13:54
Merck Korea hurries to close GM part despite union’s protest by Kim Yun-mi 2019-11-05 15:04
Takeda Korea fires union leader to worsen labor-management dispute by Kim Yun-mi 2019-11-04 15:03
Hanyang University Medical Center goes research-centered by Kim Yun-mi 2019-11-01 16:09
Huons’ insomnia cure, 2 other drugs to win insurance benefit by Kim Yun-mi 2019-10-31 13:22
라인
AbbVie’s new psoriasis drug likely to win nod this year by Kim Yun-mi 2019-10-30 16:05
Scope of AI-based medical devices expanded for licensing review by Kim Yun-mi 2019-10-30 16:03
[Special] Yongin Severance Hospital to go digital with innovation by Kim Yun-mi 2019-10-28 15:45
‘Korean hospitals equipped well to use CAR-T therapy’ by Kim Yun-mi 2019-10-23 13:17
Pfizer’s atopic drug should overcome side effects to challenge Sanofi’s Dupixent by Kim Yun-mi 2019-10-22 14:17
라인
Merck Korea forcefully shuts down general medicine biz by Kim Yun-mi 2019-10-15 15:51
Galderma Korea’s key strategy: choice and concentration by Kim Yun-mi 2019-10-15 13:56
[Special] How are Korean employees coping with big-pharma M&As? by Kim Yun-mi 2019-10-14 13:45
Sanofi to cover part of Dupixent cost for atopic dermatitis patients by Kim Yun-mi 2019-10-11 15:13
Doctors call Boehringer Ingelheim’s Jardiance marketing ‘unethical’ by Kim Yun-mi 2019-10-10 16:01
라인
Medtronic Korea denies regulatory negligence over recalled insulin pumps by Kim Yun-mi 2019-10-08 15:05
Galderma Korea workers feel insecure after separation from Nestle by Kim Yun-mi 2019-10-07 14:38
CDK4/6 inhibitor+fulvestrant combo nears getting benefit by Kim Yun-mi 2019-10-02 16:03
‘Merck Korea unilaterally lays off employees’ by Kim Yun-mi 2019-10-01 11:09
Pfizer’s leukemia therapy Besponsa to get insurance benefit by Kim Yun-mi 2019-09-26 11:26
여백
여백
여백
Back to Top